Use of at least one glycyrrhiza plant-based preparation, an antidote made from same, and the use of said antidote

Abstract

The use of at least one Glycyrrhiza plant preparation selected from the group of flour of a whole, dried Glycyrrhiza plant, flour of the leaves of the dried Glycyrrhiza plant, flour of roots of the dried Glycyrrhiza plant, aqueous dry extract of the Glycyrrhiza plant, aqueous/ethanolic dry extract of the Glycyrrhiza plant, aqueous extract of the Glycyrrhiza plant, optionally together with at least one excipient, for reducing the toxic effect of at least one polypeptide fungitoxin in agrarian products.

1 - 15 . (canceled) 
     
     
         16 . An antidote for oral application for reducing the toxic effect of at least one polypeptide fungitoxin selected from the group of enniatins, namely enniatin A, enniatin A1, enniatin B, enniatin B1, enniatin B2 or enniatin B3; beauvericin and apicidin, comprising at least one  Glycyrrhiza  plant preparation selected from the group of flour, aqueous extract, aqueous/ethanolic extract, aqueous dry extract and aqueous/ethanolic dry extract of a whole  Glycyrrhiza  plant or of roots, together with at least one excipient. 
     
     
         17 . The antidote according to  claim 16 , wherein the  Glycyrrhiza  plant is selected from the group consisting of  Glycyrrhiza glabra  and  Glycyrrhiza  uralensis. 
     
     
         18 . The antidote according to  claim 16 , wherein the aqueous dry extract comprises 4% (w/w) to 10% (w/w) glycyrrhizic acid. 
     
     
         19 . An antidote according to  claim 18 , wherein 1 mg to 100 mg, of the aqueous dry extract is used per kilogram food or feed, or an amount of at least one of the other  Glycyrrhiza  plant preparations consisting of  Glycyrrhiza glabra  and  Glycyrrhiza uralensis  with an equivalent amount of glycyrrhizic acid. 
     
     
         20 . The antidote according to  claim 16 , wherein it comprises more than 50% (w/w), of the at least one  Glycyrrhiza  plant preparation. 
     
     
         21 . The antidote according to  claim 16 , wherein the at least one excipient is selected from the group consisting of inert carriers, vitamins, minerals, phytogenic substances, enzymes and further components for detoxifying mycotoxins, namely mycotoxin-degrading enzymes, aflatoxin oxidases, ergotamine hydrolases, ergotamine amidases, zearalenone esterases, zearalenone lactonases, zearalenone hydrolases, ochratoxin amidases, fumonisin aminotransferases, fumonisin carboxyltransferases, aminopolyol aminoxidases, deoxynivalenol epoxide hydrolases, deoxynivalenol dehydrogenases, deoxynivalenol oxidases, trichothecene dehydrogenases, trichothecene oxidases; and a mycotoxin-transforming microorganisms DSM 11798; and mycotoxin-binding substances, selected from microbial cell walls or bentonite.